Healthcare Industry News: EndoBarrier
News Release - September 1, 2010
GI Dynamics Announces Distribution Agreement with Elemental Healthcare for the EndoBarrier Gastrointestinal LinerLEXINGTON, Mass. & HUNGERFORD, England--(Healthcare Sales & Marketing Network)--GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced it has entered into a new agreement with Elemental Healthcare, based in Hungerford, Berkshire, for the distribution of the EndoBarrier™ Gastrointestinal Liner in England, Wales, Scotland, Northern Ireland and Ireland. The limited agreement provides Elemental Healthcare the rights to sell and distribute the EndoBarrier within these territories. The EndoBarrier, an innovative, non-surgical therapeutic, has received CE mark approval in Europe for the treatment of type 2 diabetes and obesity and will be commercialized in certain markets later this year.
“GI Dynamics is very pleased to establish this partnership with Elemental Healthcare, a premier medical device distribution organization in the U.K.,” stated Stuart A. Randle, chief executive officer of GI Dynamics. “Elemental Healthcare’s proven sales track record, and experience in the diabetes and obesity markets and with bringing minimally invasive products to healthcare providers and surgeons, will be invaluable as the EndoBarrier becomes commercially available in select markets later this year.”
In preparation for the European launch of the EndoBarrier, GI Dynamics and Elemental Healthcare are identifying, training and designating Centers of Excellence and expanding clinical experience with the EndoBarrier. The Centers of Excellence participating in this effort in the U.K. include St. Anthony’s Hospital, Imperial College/St. Mary’s Hospital, National Obesity Surgery Center (Manchester) and Southampton University Hospital. Designated Centers of Excellence will have exclusive access over the next several months to the EndoBarrier as a cornerstone of an overall patient care program to treat patients with type 2 diabetes and obesity.
Adam Power, managing director, Elemental Healthcare commented, “The epidemic of type 2 diabetes and obesity is an issue that cannot afford to be ignored and EndoBarrier addresses both of these concerns. We are excited about our partnership with GI Dynamics and proud that we can now offer U.K. and Northern Ireland-based physicians the most advanced non-surgical technology available on the market.”
About the EndoBarrier™ Gastrointestinal Liner
The EndoBarrier is a non-surgical therapy to treat type 2 diabetes and obesity approved for use in Europe and in advanced stages of clinical development in the United States. Clinical trials to date involving more than 300 patients have demonstrated significant weight loss and diabetes improvement with the EndoBarrier Gastrointestinal Liner.
The EndoBarrier Gastrointestinal Liner is placed in the GI tract endoscopically (via the mouth) to create a barrier between food and the wall of the intestine. Physicians believe that preventing food from coming into contact with the intestinal wall may alter the activation of hormonal signals that originate in the intestine, thus mimicking the effects of a Roux-en-Y gastric bypass procedure without surgery. A growing body of preclinical and clinical evidence supports the potential for the EndoBarrier Gastrointestinal Liner to change the treatment landscape for patients who are obese and living with type 2 diabetes, and patients with severe weight problems.
About Elemental Healthcare
Elemental Healthcare Ltd is a leading medical device company providing innovative solutions in Minimally Invasive Surgery. Working with market leading companies, Elemental Healthcare Ltd has brought together a unique and exciting portfolio. For more information, visit Elemental Healthcare online at www.elementalhealthcare.co.uk.
About GI Dynamics
GI Dynamics is focused on developing effective, non-surgical approaches for treating type 2 diabetes and obesity. The company’s patented EndoBarrier™ Technology has the potential to deliver medical interventions for patients combating weight problems and diabetes or diabetes risk factors. Data from clinical trials demonstrate that the EndoBarrier Gastrointestinal Liner, an advanced device in the EndoBarrier portfolio, may provide rapid improvement in glycemic control and significant weight loss by modifying metabolic pathways. GI Dynamics is collaborating with experts in endocrinology, gastroenterology, bariatric surgery and medical weight loss on these efforts.
Based in Lexington, Massachusetts and founded in 2003, GI Dynamics is backed by top-tier investors including Advanced Technology Ventures, Catalyst Health Ventures, Cutlass Capital, Domain Associates, Johnson & Johnson Development Corporation, Medtronic, Inc., and Polaris Venture Partners. For more information, visit GI Dynamics online at www.gidynamics.com.
Source: GI Dynamics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.